Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 5/20 | 0.63 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.63 |
| ▸ | NPC1 | O15118 | 3/20 | 0.63 |
| ▸ | EPHX2 | P34913 | 3/20 | 0.58 |
| ▸ | NAMPT | P43490 | 3/20 | 0.56 |
| ▸ | IDO1 | P14902 | 1/20 | 0.55 |
| ▸ | MAPT | P10636 | 1/20 | 0.52 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.51 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.51 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.51 |
| ▸ | HPGD | P15428 | 1/20 | 0.51 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.51 |
| ▸ | MEN1 | O00255 | 3/20 | 0.49 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.49 |
| ▸ | GAA | P10253 | 1/20 | 0.49 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | PKM | P14618 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3709185 | 0.93 | RAB9A (0.73) | RAB9AKMT2ANPC1EPHX2NAMPT | |
| SCHEMBL7401491 | 0.84 | KMT2A (0.87) | RAB9AKMT2ANPC1EPHX2NAMPT | |
| SCHEMBL3332768 | 0.82 | KMT2A (0.63) | RAB9AKMT2ANPC1EPHX2NAMPT | |
| SCHEMBL7008242 | 0.82 | IDO1 (0.76) | RAB9AKMT2ANPC1EPHX2NAMPT | |
| SCHEMBL17244556 | 0.82 | POLB (0.63) | RAB9AKMT2ANPC1EPHX2NAMPT | |
| SCHEMBL11208728 | 0.81 | EPHX2 (0.83) | RAB9AKMT2ANPC1EPHX2NAMPT | |
| SCHEMBL12545832 | 0.81 | L3MBTL1 (0.65) | RAB9AKMT2ANPC1EPHX2NAMPT | |
| SCHEMBL7901196 | 0.79 | RAB9A (0.59) | RAB9AKMT2ANPC1EPHX2NAMPT | |
| SCHEMBL3453739 | 0.78 | EPHX2 (0.71) | RAB9AKMT2ANPC1EPHX2NAMPT | |
| SCHEMBL17729122 | 0.77 | RAB9A (0.56) | RAB9AKMT2ANPC1EPHX2NAMPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8735584-B2 | Protein kinase inhibitors and use thereof | MERCK PATENT GMBH (DE) | 2014-05-27 | — | — | US | disclosed |
| CN-101952287-B | Protein kinase inhibitors and use thereof | MERCK SERONO SA | 2013-11-27 | — | — | CN | disclosed |
| US-8569295-B2 | Bicyclic urea compounds | MERCK PATENT GMBH (DE) | 2013-10-29 | — | — | US | disclosed |
| EP-2461869-B1 | NOVEL BICYCLIC UREA COMPOUNDS | MERCK PATENT GMBH (DE) | 2013-08-21 | — | — | EP | disclosed |
| CN-101610767-B | Combination therapy of substituted oxazolidinones | BAYER SCHERING PHARMA AG | 2013-03-13 | — | — | CN | disclosed |
| EP-2254889-B1 | PROTEIN KINASE INHIBITORS AND USE THEREOF | MERCK PATENT GMBH (DE) | 2012-12-19 | — | — | EP | disclosed |
| US-20120190654-A1 | NOVEL BICYCLIC UREA COMPOUNDS | MERCK PATENT GMBH (DE) | 2012-07-26 | — | — | US | disclosed |
| CN-102573994-A | Novel bicyclic urea compounds | MERCK PATENT GMBH | 2012-07-11 | — | — | CN | disclosed |
| EP-2461869-A1 | NOVEL BICYCLIC UREA COMPOUNDS | Merck Patent GmbH (DE) | 2012-06-13 | — | — | EP | disclosed |
| US-20110053906-A1 | PROTEIN KINASE INHIBITORS AND USE THEREOF | MERCK PATENT GMBH (DE) | 2011-03-03 | — | — | US | disclosed |
| WO-2011017142-A1 | NOVEL BICYCLIC UREA COMPOUNDS | MERCK PATENT GMBH (DE) | 2011-02-10 | — | — | WO | disclosed |
| CN-101952287-A | Kinases inhibitor and application thereof | MERCK SERONO SA | 2011-01-19 | — | — | CN | disclosed |
| EP-2254889-A1 | PROTEIN KINASE INHIBITORS AND USE THEREOF | Merck Patent GmbH (DE) | 2010-12-01 | — | — | EP | disclosed |
| CN-100577162-C | The oxazolidinones that is used for the replacement of therapeutic alliance | BAYER HEALTHCARE AG | 2010-01-06 | — | — | CN | disclosed |
| CN-101610767-A | The combination treatment of the oxazolidinones that is substituted | BAYER HEALTHCARE AG (DE) | 2009-12-23 | — | — | CN | disclosed |
| WO-2009108670-A1 | PROTEIN KINASE INHIBITORS AND USE THEREOF | MERCK SERONO S.A. (CH) | 2009-09-03 | — | — | WO | disclosed |
| CN-101325957-A | Microangiopathy treatment and prevention | BAYER HEALTHCARE AG (DE) | 2008-12-17 | — | — | CN | disclosed |
| CN-101321533-A | Combination therapy with substituted * oxazolidinones for the prevention and treatment of cerebral blood flow disorders | BAYER HEALTHCARE AG (DE) | 2008-12-10 | — | — | CN | disclosed |
| CN-1523986-A | Substituted oxazolidinones for combinational therapy | �����ɷ� | 2004-08-25 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120190654-A1 | NOVEL BICYCLIC UREA COMPOUNDS | CCNC, CCNI, CCNA1 | RAB9A 1974/4885KMT2A 708/4885NPC1 1489/4885 |
| US-20110053906-A1 | PROTEIN KINASE INHIBITORS AND USE THEREOF | MAP4K2, MAP3K20, MAP4K1 | RAB9A 1390/4885KMT2A 2055/4885NPC1 3403/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.